Desmopressin (DDAVP) treatment in adult sleep-related enuresis

Gregory Katz, Baruch Spivak, Roberto Mester, Alex Grinshpoon, Abraham Weizman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


In an open prospective study we investigated the efficacy of intranasal administration of 1-desamino-8-D-arginine vasopressin (DDAVP) in enuretic adults during military service. Twelve male enuretic soldiers aged 18-19 years (18.9 ± 0.5 years), with a history of resistance to tricyclic antidepressant treatment and to behavioural therapy, were included in the study. Patients were treated with 20-40 mg (bedtime dose) DDAVP. A significant decrease in the frequency of enuresis was demonstrated (3.4 ± 4.3 versus baseline of 8.2 ± 3.3 days, p = 0.01). Four patients achieved complete dryness and four patients achieved partial response. It seems that intranasal DDAVP can be an effective and safe treatment in young adult sleep-related enuresis.

Original languageEnglish
Pages (from-to)505-507
Number of pages3
JournalHuman Psychopharmacology
Issue number5
StatePublished - Sep 1997


  • 1-desamino-8-D-arginine vasopressin (DDAVP desmopressin)
  • Sleep-related enuresis
  • Tricyclic antidepressants


Dive into the research topics of 'Desmopressin (DDAVP) treatment in adult sleep-related enuresis'. Together they form a unique fingerprint.

Cite this